Moleculin Biotech, Inc.
MBRXMoleculin Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing oncology drugs and treatments for difficult-to-treat cancers. The company specializes in the research and development of small molecule therapeutics targeting cancer metabolism, tumor microenvironment, and resistant cancer cells. Moleculin's pipeline includes compounds designed for oral administration, aiming to address unmet medical needs in oncology.
Company News
The global cell therapy manufacturing market is projected to reach $14 billion by 2035, driven by over 1,000 active clinical candidates. FDA regulatory flexibility is accelerating timelines for cell and gene therapy approvals. Several biotech companies are advancing scalable manufacturing capabilities and clinical programs: Avaà Bio is producing...
Moleculin Biotech (MBRX) released a CEO Corner segment discussing progress on its pivotal Phase 3 MIRACLE Study evaluating Annamycin combined with cytarabine for relapsed or refractory acute myeloid leukemia. The adaptive trial includes an initial cohort of 45 patients with interim unblinding planned after treatment completion. Enrollment and dos...
Over 100 pharmaceutical companies are actively developing 150+ pipeline drugs for Acute Myeloid Leukemia (AML), with approximately 10 drugs in late-stage development and 50+ in mid and early stages, focusing on targeted therapies and personalized treatment approaches.
Moleculin reported positive results from a Phase 1B/2 clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma lung metastases. The trial showed improved overall survival and progression-free survival, with a clinical benefit rate of 59.4%.
Moleculin Biotech, a late-stage pharmaceutical company, presented its top five reasons for why investors should pay attention to the company in 2025, including updates on its lead drug candidate Annamycin and other pipeline programs.
